| Archive | |
| |
| December 2006, Volume 95, Supplement 1 | |
| |
Histone Deacetylase (HDAC) Inhibition-A Novel Approach to Cancer Treatment Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington DC, USA Guest Editor: Bruce D Cheson, MD | |
 | |
 | |
| Introduction | back to top |
| |
Histone deacetylase inhibition: a novel approach to cancer treatment B D Cheson | |
| Abstract | Full Article | PDF |
S1 |
| |
| Articles | back to top |
| |
Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor V M Richon | |
| Abstract | Full Article | PDF |
S2 |
Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma O A O'Connor | |
| Abstract | Full Article | PDF |
S7 |
Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma M Duvic & C Zhang | |
| Abstract | Full Article | PDF |
S13 |
| In this issue | |
| ||
 | Introduction | |
| Articles | |
| ||
| ||
| ||
 | Preceding issue | |
 | Next issue | |
| ||
| ||
| ||
|
| ||
| ||
 | ||
|
|
|
|
| |||
| Print ISSN: 0007-0920 | Online ISSN: 1532-1827 | © 2006 Cancer Research UK | ||
| |||
| Privacy Policy | |||